What type of study is this?

This is a Pre-Registered Trial study.

Therapeutic Effects and Safety of Mirtazapine for Insomnia in Major Depressive Disorder: Findings from a 6-Week Open-Label Pre- and Post-Intervention Study

View Full Paper

Ask AI

Bookmark

Authors

Open-label trial shows mirtazapine significantly reduces insomnia and depression symptoms in adults, indicating improved quality of life.

Mirtazapine treatment significantly reduced insomnia in patients with major depressive disorder, leading to improved quality of life.
On day 42, 62.4% of patients reported insomnia remission and 41.3% experienced depression remission following mirtazapine treatment.
Assessment utilized the Hamilton Depression Rating Scale and Insomnia Severity Index, with high patient completion rates at 80.7% during the trial.
Common adverse effects included increased appetite and weight gain, which may impact treatment adherence and quality of life.

Alam et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark